LDS/Medical Tests/ClonoSeq Assay

ClonoSeq Assay

The clonoSEQ Assay is an in vitro diagnostic that uses multiplex polymerase chain reaction (PCR) and next-generation sequencing (NGS) to identify and quantify rearranged IgH (VDJ), IgH (DJ), IgK and IgL receptor gene sequences, as well as translocated BCL1/IgH (J) and BCL2/IgH (J) sequences in DNA extracted from bone marrow in patients with B-cell acute lymphoblastic leukemia (ALL) or multiple myeloma (MM), and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). The clonoSEQ Assay measures minimal residual disease (MRD) to monitor changes in disease burden after treatment.

Minimal Residual Disease (MRD) refers to the presence of leukemic cells below the threshold of detection by conventional morphologic methods or standard immunophenotyping. Clinical practice guidelines in select hematological malignancies recognize that MRD status is a reliable indicator of clinical outcome and response to therapy. Studies in select hematological malignancies have demonstrated the strong correlation between MRD and risks for relapse, as well as the prognostic significance of MRD measurements after therapy.

A positive finding with the assay indicates the presence of disease after the treatment and can aid in predicting outcome and determining subsequent treatment. MRD assessment by flow cytometry or molecular methods is recommended to monitor patients with acute lymphoid leukemia, multiple myeloma, and chronic lymphocytic leukemia who have recently undergone therapy.

  • Monitoring minimal residual disease in ALL, MM and CLL
  • Therapy treatment and disease management
  • Helpful in predicting clinical outcome of the patient
A positive MRD test result indicates the presence of cancer cells/sequence after treatment. A negative MRD test result indicates the absence of cancer cells/sequence after treatment.

Negative for MRD (No cancer cells detected)

Multiplex PCR and Next generation sequencing (NGS).

Whole blood (Lavender-top EDTA tube), Bone marrow aspirate (Lavender-top EDTA) tube.

Stability Whole Blood

  • Ambient: 5 days
  • Refrigerated: 14 days
  • Frozen: 6 months

Stability Bone marrow aspirate

  • Ambient: 3 days
  • Refrigerated: 7 days
  • Frozen: 18 months
Complete blood count with differential, peripheral blood examination, bone marrow examination, immunophenotyping, and fluorescent in-situ hybridization (FISH), flow cytometry.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login